Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | TERT | O14746 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | TOP1 | P11387 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250221 | 0.93 | EP300 (0.48) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL28596922 | 0.81 | EP300 (0.55) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL28526728 | 0.81 | EP300 (0.55) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL28541122 | 0.81 | EP300 (0.55) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL10532348 | 0.79 | EP300 (0.52) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL19411365 | 0.79 | EP300 (0.52) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL19411366 | 0.79 | EP300 (0.52) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL3292785 | 0.79 | PPARG (0.54) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL17652255 | 0.79 | MAPT (0.56) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL1536891 | 0.79 | PPARG (0.71) | PPARGPPARATERTPTPN1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546419-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8247427-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-21 | — | — | US | disclosed |
| US-8101164-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120004255-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| EP-1667726-B1 | POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM | GEN HOSPITAL CORP (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7790150-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070190018-A1 | Dual phase drug release system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | disclosed |
| EP-1667726-A2 | POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005023294-A2 | POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | PPARG 4095/4885PPARA 3702/4885TERT 4681/4885 |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | PPARG 4154/4885PPARA 3807/4885TERT 4661/4885 |
| US-20070190018-A1 | Dual phase drug release system | SUCNR1, SUCLA2, SUCLG2 | PPARG 4036/4885PPARA 3658/4885TERT 4670/4885 |
| US-20120004255-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | PPARG 4154/4885PPARA 3807/4885TERT 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.